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Abstract
 
The regulation of 
 
ob
 
 gene expression in abdominal subcuta-
neous adipose tissue was investigated using a reverse tran-
scription-competitive PCR method to quantify the mRNA
level of leptin. Leptin mRNA level was highly correlated
with the body mass index of 26 subjects (12 lean, 7 non–insu-
lin-dependent diabetic, and 7 obese patients). The effect of
fasting on 
 
ob
 
 gene expression was investigated in 10 subjects
maintained on a hypocaloric diet (1045 KJ/d) for 5 d. While
their metabolic parameters significantly changed (decrease
in insulinemia, glycemia, and resting metabolic rate and in-
crease in plasma ketone bodies), the caloric restriction did
not modify the leptin mRNA level in the adipose tissue. To
verify whether insulin regulates 
 
ob
 
 gene expression, six lean
subjects underwent a 3-h euglycemic hyperinsulinemic
(846
 
6
 
138 pmol/liter) clamp. Leptin and Glut 4 mRNA lev-
els were quantified in adipose tissue biopsies taken before
and at the end of the clamp. Insulin infusion produced a sig-
nificant threefold increase in Glut 4 mRNA while leptin
mRNA was not affected. It is concluded that 
 
ob
 
 gene ex-
pression is not acutely regulated by insulin or by metabolic
factors related to fasting in human abdominal subcutaneous
adipose tissue. (
 
J. Clin. Invest.
 
 1996. 98:251–255.) Key
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Introduction
 
Recently, the mouse 
 
ob
 
 gene (1), and subsequently its human
and rat homologues (1–5), have been cloned. Leptin, the prod-
uct of 
 
ob
 
 gene (6), is produced by the adipocytes and consid-
ered as a hormone that acts centrally to regulate body weight
homeostasis through the control of appetite and energy expen-
diture (1, 6–10). Mutations in the 
 
ob
 
 gene, as seen in the 
 
ob
 
/
 
ob
 
mice (1), or in the 
 
ob
 
 receptor locus, as observed in 
 
db
 
/
 
db
 
 mice
(11), result in extreme obesity in these animal models. In ro-
dents, the 
 
ob
 
 gene is highly regulated and is under control of
various hormonal and metabolic factors. Leptin mRNA levels
are correlated with the nutritional status being markedly re-
duced after fasting and increased by refeeding (12–16). These
changes in 
 
ob
 
 expression seem secondary to changes in circu-
lating insulin levels, since 
 
ob
 
 gene expression is positively reg-
ulated by insulin both in vivo and in vitro (12, 13).
The relevance of leptin to human obesity is less clear. As of
yet no mutation in the human 
 
ob
 
 gene or absence of leptin ex-
pression has been reported in obese subjects (17). In contrast
several studies report a positive correlation between body
mass index and leptin mRNA or plasma concentrations (17–
21). This situation is reminiscent of the overexpression of lep-
tin mRNA observed in several obese animals such as the 
 
db
 
/
 
db
 
mice, the hypothalamus-lesioned rats and the zucker 
 
fa
 
/
 
fa
 
 rats
(4–6, 16, 22–24). This implies that obese animals and humans
are unresponsive or resistant to the effects of leptin and ques-
tions the suggested role of leptin as a satiety factor, which con-
trols food intake and/or energy expenditure.
In this study we investigated the regulation of leptin
mRNA abundance in human subcutaneous abdominal adipose
tissue in response to either insulin infusion or fasting. Our data
confirm the correlation between leptin mRNA levels and the
body mass index, previously observed by others (20, 21). Inter-
estingly, neither insulin infusion nor a caloric restriction during
a 5 day period significantly modified leptin mRNA levels. This
indicates that human 
 
ob
 
 gene expression, unlike rodent 
 
ob
 
gene expression, is not subject to an acute control by nutri-
tional and hormonal factors, such as insulin. Our data question
the role of human leptin as a tightly controlled satiety factor
but rather suggest that leptin signals the size of the adipose tis-
sue deposit.
 
Methods
 
Subjects and protocols.
 
26 subjects (11 men and 15 women, mean
[
 
6
 
SD] age 36
 
6
 
13 years) participated in the study. All gave their writ-
ten consent after being informed of the nature, purpose, and possible
risks of the study. The experimental protocol was approved by the
ethics committee of Hospices Civils de Lyon and performed accord-
ing to the French legislation (Hurriet law).
Seven subjects suffered from morbid obesity (body mass index
(BMI)
 
1
 
5
 
 45.1
 
6
 
5.8 Kg/m
 
2
 
, range 36.6–53.4) and were treated by verti-
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cal banded gastroplasty. At the time of surgery, patients were on their
maximal lifetime weight and were not on restricted diet. None of
them were taking any medication or had any evidence of metabolic
disease other than obesity. Their fasting glycemia was 5.6
 
6
 
0.7 mM,
their fasting insulinemia was 146
 
6
 
43 pmol/liter. Biopsies of subcuta-
neous adipose tissue were performed during the surgery after an
overnight fast, and frozen in liquid nitrogen immediately.
We studied 12 normal lean subjects (BMI 
 
5
 
 21.8
 
6
 
1.8 Kg/m
 
2
 
),
from whom six underwent a 3-h euglycemic hyperinsulinemic clamp
(insulin infusion rate of 12 pmol/Kg.min) (25) in order to determine
the acute effect of insulin on 
 
ob
 
 gene expression. The study was per-
formed after an overnight fast. Biopsies of the abdominal subcutane-
ous adipose tissue were performed 2 h before and at the end of the
euglycemic hyperinsulinemic clamp. After cleaning and infiltration of
the skin with 2% xylocaïne, adipose tissue was aspirated through a
15-gauge needle. Samples averaged 131
 
6
 
62 mg wet weight. They
were immediately frozen in liquid nitrogen and stored at 
 
2
 
80
 
8
 
C until
analysis.
10 subjects participated in a five day study protocol during which
they received a 1045 KJ/d diet in order to study the effect of fasting
on 
 
ob
 
 gene expression. Seven of these subjects were overweight and
had non–insulin-dependent diabetes mellitus (NIDDM) (BMI 
 
5
 
31.2
 
6
 
2.7 Kg/m
 
2
 
, ranging from 25.9 to 34.4; fasting plasma glucose
concentration 
 
5
 
 13.4
 
6
 
3.3 mM). Three normal weight subjects served
as lean controls (BMI 
 
5
 
 21.9
 
6
 
1.5 Kg/m
 
2
 
, glycemia 
 
5
 
 4.5
 
6
 
0.2 mM).
The reported body weight of the subjects was stable for at least one
month. For the patients with NIDDM, usual treatment with oral an-
tidiabetic agents was interrupted at least one week before admission.
The subjects entered the hospital 3 d before the beginning of the
study protocol. During these 3 d, their diet was standardized (104 KJ/
kg per day). The first biopsy of abdominal subcutaneous adipose tis-
sue was performed after an overnight fast, just before starting the pe-
riod of caloric restriction. The second biospy was taken on the morn-
ing of the sixth day of caloric restriction. Before and after the diet, the
resting metabolic rate of the subjects was measured by indirect calo-
rimetry (Datex Deltatrac Monitor, Helsinski, Finland) (26). Blood
and urine samples were collected each day to measure glucose and
ketone bodies concentrations.
 
Total RNA preparation.
 
Adipose tissue samples were pulverized
in liquid nitrogen and total RNA was prepared from the frozen pow-
der using the RNeasy total RNA kit (QIAGEN, Chatsworth, CA)
following the instructions of the manufacturer. The ratio of absorp-
tion (260/280 nm) of all preparations was between 1.9 and 2.0 and the
mean yield of total RNA was 21
 
6
 
9 
 
m
 
g/g of tissue (mean
 
6
 
SD, 
 
n
 
 
 
5
 
 42
preparations) with no significant difference between the different
groups of subjects. The yield of total RNA was also not significantly
different between the biopsies taken before and at the end of the eu-
glycemic hyperinsulinemic clamp, or between the biopsies taken be-
fore and after the caloric restriction period (data not shown).
 
Quantification of leptin mRNA.
 
Human leptin mRNA was quan-
tified in adipose tissue total RNA preparations by reverse transcrip-
tion reaction followed by competitive polymerase chain reaction
(RT-competitive PCR) which consist in the co-amplification of leptin
cDNA with known amount of a leptin competitor DNA in the same
test tube (27, 28). The competitor DNA molecule was derived from
the clone Ob6.1 that contained the complete coding sequence of hu-
man leptin cDNA (3). This clone was obtained by screening a human
adipose tissue 
 
l
 
gt 11 cDNA library with a fragment of mouse 
 
ob
 
cDNA clone pmob (29), and subcloned into the phagemid pBlue-
Script SK (Stratagene). The leptin competitor was constructed by de-
leting a 80 bp-long fragment (nucleotides 
 
1
 
324 to 
 
1
 
404 of the coding
sequence) by digestion (Eco72I/ HindIII) and ligation. The RT-PCR
was performed with 23-nucleotide-long primers that hybridized to the
3
 
9
 
 and 5
 
9
 
 ends of the leptin coding sequence (sense primer: 5
 
9
 
-ATG-
CATTGGGGAACCCTGTGCGG-3
 
9
 
, located at position 
 
1
 
1 to 
 
1
 
23;
antisense primer: 5
 
9
 
-TGAGGTCCAGCTGCCACAGCATG-3
 
9
 
, lo-
cated at position 
 
1
 
465 to 
 
1
 
487). Therefore, leptin mRNA yielded a
PCR product of 487 bp while the amplification of the competitor gave
a product of 407 bp. Working solutions of the leptin competitor DNA
at defined concentrations (50–10
 
2
 
3
 
 pmol/liter) were prepared by se-
rial dilution in 10 mM Tris-HCl (pH 8.3)-1 mM EDTA buffer.
The conditions of the reverse transcription reaction and of the
competitive PCR were the same as we previously used to quantify in-
sulin receptor mRNAs in rat tissues (28). Briefly, the RT reaction was
performed from 0.5 
 
m
 
g of adipose tissue total RNA with a thermo-
stable reverse transcriptase during 15 min at 70
 
8
 
C. The RT medium
was then added to a PCR mix that was aliquoted in four PCR tubes,
each containing a different, but known, amount of leptin competitor
DNA. The tubes were subjected to 40 cycles of amplification includ-
ing denaturation for 60 s at 94
 
8
 
C, hybridation for 60 s at 58
 
8
 
C and
elongation for 90 s at 72
 
8
 
C. The PCR products were separated in 3%
agarose gel and the amount of leptin mRNA in the reaction was de-
termined at the competition equivalence point of the band densities
as previously described (28).
To validate the RT-competitive PCR assay, human leptin RNA
was synthetized by in vitro translation from the clone Ob6.1 (Ribo-
probe system, Promega), and quantified by RT-competitive PCR
over a wide range of concentrations (from 0.5 to 25 amol added in the
RT reaction). The standard curve obtained was linear over the tested
range (
 
r
 
 
 
5
 
 0.987) with a slope of 1.06. The inter-assay variation of the
RT-competitive assay was less than 10% with six separate determina-
tions of the same amount of leptin RNA.
In addition to leptin mRNA, we measured Glut 4 mRNA levels in
the biopsies taken before and at the end of the euglycemic hyperin-
sulinemic clamp. Glut 4 mRNA was also quantified by RT-competitive
PCR assay, with a specific competitor DNA molecule. The construc-
tion of the competitor DNA and the validations of the RT-competi-
tive PCR for Glut 4 are presented elsewhere (30).
 
Results presentation. 
 
All the results are expressed as means
 
6
 
SD.
Statistical analysis were performed with a Wilcoxon nonparametric
test for paired values. The threshold for significance was set at 
 
P
 
 
 
,
 
0.05.
 
Results
 
To analyze whether leptin mRNA levels correlate with adi-
pose tissue mass, leptin mRNA was quantified in the subcuta-
neous abdominal adipose tissue of 26 subjects after an over-
night fast. The absolute leptin mRNA level was about eight
times lower (
 
P
 
 
 
,
 
 0.001) in the normal weight subjects
(12.2
 
6
 
7.1 amol/
 
m
 
g total RNA, 
 
n
 
 
 
5
 
 12) than in the subjects
with morbid obesity (94
 
6
 
34 amol/
 
m
 
g total RNA, 
 
n
 
 
 
5
 
 7). Lep-
tin mRNA content of the adipose tissue was strongly corre-
lated with the BMI (
 
r
 
 
 
5
 
 0.897, 
 
P
 
 
 
,
 
 0.001; Spearman correla-
tion test) (Fig. 1) and with the body weight of the subjects (
 
r
 
 
 
5
 
0.810, 
 
P
 
 
 
,
 
 0.001). There was no correlation between leptin
mRNA levels and the amount of tissue sampled or the yield in
total RNA.
Next, we investigated the effects of a caloric restriction on
leptin mRNA levels. Seven overweight NIDDM patients with
elevated basal level of leptin mRNA (68
 
6
 
14 amol/
 
m
 
g of total
RNA) and three control subjects (22.2
 
6
 
1.6 amol/
 
m
 
g of total
RNA) were maintained on a restricted diet of 1045 KJ/d for
5 d. The diet induced a mean weight loss of 3
 
6
 
2 Kg (range 1–6
Kg) in all the subjects, which corresponded to a reduction of
their original body weight by 3.7
 
6
 
2.1%. In the NIDDM pa-
tients, the plasma 
 
b
 
-hydroxybutyrate concentrations increased
from 0.6
 
6
 
1 to 1.9
 
6
 
1.4 mM (
 
P
 
 
 
,
 
 0.001) while fasting glycemia
decreased from 13.463.3 to 8.662.2 mM (P , 0.01) and fasting
insulin concentrations from 78627 to 53620 pmol/liter (P ,
0.01). Increase in plasma ketone bodies concentration (from
0.1760.12 to 2.1461.13 mM) and decreases in glycemia (from
4.560.2 to 3.560.5 mM) and insulinemia (from 50610 to 2866
Downloaded from http://www.jci.org on January 11, 2016.   http://dx.doi.org/10.1172/JCI118786
Regulation of ob Gene Expression in Human Adipose Tissue 253
pmol/liter) were also observed in the control subjects. During
the caloric restriction period, all the subjects were hungry and
their resting metabolic rate, measured by indirect calorimetry,
decreased by 8.565.5% (P , 0.01) from 635861087 to 57856
848 KJ/d. Fig. 2 shows that the abundance of leptin mRNA in
the adipose tissue did not change significantly during the ca-
loric restriction. The average modification induced by the diet
was 117%, varying from a 46% diminution to a 69% increase.
The large variability in basal leptin mRNA levels in this group
was related to the difference in BMI of the subjects (Fig. 1). In
addition, we found that there was no relationship between
changes in the levels of leptin mRNA and changes in the rest-
ing metabolic rate of the subjects measured by indirect calo-
rimetry before and after the diet (not shown).
Finally, we analyzed whether changes in circulating insulin
concentration affect leptin mRNA levels in human adipose tis-
sue, as reported in rodent models (12). To this aim, six normal
subjects underwent a 3-h euglycemic hyperinsulinemic clamp.
During the clamp, insulin concentrations rose from 49623 to
8466138 pmol/liter whereas glycemia was maintained constant
at 4.160.2 mM (glucose infusion rate 5 52.867.7 mmol/
Kg.min). Plasma non-esterified fatty acid concentrations de-
creased from 0.460.2 mM to 0.0460.01 mM (P , 0.001) dur-
ing the clamp. Fig. 3 (upper panel) clearly shows that leptin
mRNA level did not change during insulin infusion. To verify
whether 3 h of insulin infusion is able to modify gene expres-
sion in human adipose tissue, we measured in parallel the
abundance of Glut 4 mRNA in the same biopsies. In contrast
to leptin mRNA levels, Glut 4 mRNA increased significantly
(P 5 0.002) during the euglycemic hyperinsulinemic clamp in
all subjects but one (Fig. 3, lower panel).
Figure 1. Correlation of leptin mRNA levels with body mass index. 
The absolute amounts of leptin mRNA were determined by RT-com-
petitive PCR in abdominal subcutaneous adipose tissue biopsies as 
described in Methods. The equation of the regression was : y 5 
259.8 1 3.5 X, r 5 0.897 with P , 0.001.
Figure 2. Effect of 5 days of caloric restriction on leptin mRNA lev-
els. The absolute amounts of leptin mRNA were determined in the 
adipose tissue of 7 NIDDM patients (circle) and 3 control subjects 
(square) before and after 5 d of hypocaloric diet (1045 KJ/d).
Figure 3. Effect of insulin infusion on leptin and Glut 4 mRNA lev-
els. The absolute amounts of leptin (upper panel) and Glut4 (lower 
panel) mRNA were measured in the adipose tissue of six control sub-
jects before and at the end of 3 h of euglycemic hyperinsulinemic 
clamp as described in Methods.
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Discussion
In this study, we investigated the in vivo regulation of the hu-
man ob gene expression estimated by the quantification of lep-
tin mRNA in abdominal subcutaneous adipose tissue. Leptin,
the product of ob gene, modulates body weight and energy
balance in mouse (6–10) and ob gene expression is closely re-
lated to the nutritional status and the levels of circulating insu-
lin in rodents (12–16). Therefore, leptin is considered as a sati-
ety factor that could control food intake and/or energy
expenditure in these models. In human, plasma leptin concen-
trations and adipose tissue mRNA abundance correlate with
the body mass index and the percentage of body fat (17, 20,
21), but the in vivo regulation of ob gene expression has not
been yet studied.
To investigate the regulation of ob gene expression in hu-
man, we developped a RT-competitive PCR based assay (27,
28) which allows to determine the absolute concentration of
leptin mRNA. It is well demonstrated that standard RT-PCR
should not be used as a quantitative assay to measure a given
mRNA, mainly because of the uncontrolled efficiency of the
PCR (27, 31). The addition of a competitor DNA molecule
which is amplified in the same test tube and with the same
primers as the target mRNA overcomes this problem allowing
real quantitation (27, 28, 30, 31). Using known amounts of in
vitro synthetized leptin RNA, we confirmed that the RT-com-
petitive PCR assay developed in this work is quantitative, re-
producible and very sensitive. It allows the accurate determi-
nation of leptin mRNA down to 0.5 10218 moles in the assay
which corresponds to z 300,000 molecules of leptin mRNA. In
view of the low yields in total RNA in human adipose tissue
and in view of the low levels of leptin mRNA in normal weight
subjects, this RT-competitive PCR assay, allowing measure-
ment of minute amounts of mRNA, is a powerfull method to
study variations in leptin mRNA and thus to investigate the
regulation of ob gene expression in vivo.
Absolute levels of leptin mRNA in the abdominal subcuta-
neous adipose tissue showed large differences between the in-
dividuals. Leptin mRNA was about eightfold higher in pa-
tients with morbid obesity relative to lean normal subjects and
strongly correlated with the BMI of the subjects. This observa-
tion confirmed recent findings (17, 20, 21) and thus served as
an additional validation of our RT-competitive assay. Interest-
ingly, the leptin mRNA levels of patients with NIDDM also
correlated positively with their BMI, suggesting that the ex-
pression of ob gene is mainly related to the fat mass of the sub-
jects rather than to the metabolic and hormonal changes asso-
ciated with NIDDM.
If leptin is a satiety factor in humans, it could be expected
that its expression correlates with changes in the nutritional
status and/or with modifications in the circulating insulin con-
centrations, as it has been demonstrated in rodents models
(12–16). To test this hypothesis, we investigated the regulation
of ob gene expression in two defined situations. In a first ex-
periment, calory intake was restricted for 5 d in a group of
overweight subjects to verify the effects of fasting on ob gene
expression. Caloric restriction is associated with complex met-
abolic adaptations involving numerous hormonal changes
which include a decreased insulin/glucagon ratio (32). As a
consequence, lipolysis and b-oxidation of fatty acids are en-
hanced resulting in increased levels of circulating ketone bod-
ies such as b-hydroxybutyrate (32). Therefore, the observed
changes in glucose, insulin and b-hydroxybutyrate concentra-
tions in this study are indicative of an efficient caloric restric-
tion in the subjects maintained on the hypocaloric diet. More-
over, their resting metabolic rate decreased significantly
during the period of caloric restriction. Interestingly, and in
contrast to data obtained in rodents, the caloric restriction was
not associated with a significant change in leptin mRNA levels.
This suggests therefore that ob gene expression is not con-
trolled by metabolic factors related to caloric restriction and
fasting in humans. Our data seem, however, to be in apparent
conflict with the data generated by Maffei et al. (20) and by
Considine et al. (21) who observed a decrease in leptin mRNA
and protein levels in very obese patients after long-term ca-
loric restriction. However, the diet resulted in a substantial de-
crease in body weight and BMI in their patients (20, 21) and
therefore, the observed decrease in leptin mRNA level might
be associated with the loss in adipose tissue mass. In contrast,
short-term caloric restriction with a tiny decrease in body
weight and BMI as observed in our study did not affect leptin
mRNA levels. Taken together, these observations are in line
with the results of Hamilton et al. (19), who demonstrated that
leptin expression is positively correlated with adipocyte hyper-
trophy and hyperplasia.
In a second experiment, plasma insulin concentration was
maintained at supraphysiological levels during 3 h in a group
of control subjects to investigate the acute effect of insulin on
ob gene expression. Leptin mRNA levels in the adipose tissue
did not change during the hyperinsulinemic clamp. The lack of
variations of leptin mRNA during insulin infusion contrasted
with the observation of significant increase in glucose trans-
porter (Glut 4) mRNA levels in the same tissue biopsies. In-
creased mRNA levels of Glut 4 during euglycemic hyperin-
sulinemic clamp has already been reported in normal human
skeletal muscle (30, 33). However, the regulation of Glut 4 ex-
pression by insulin is incompletely understood. Diabetes and
fasting decrease Glut 4 mRNA level, whereas feeding restores
it in animal models, suggesting a positive role of insulin in the
control of Glut 4 gene expression (34). On the other hand,
chronic insulin administration reduces the transcription of
Glut 4 gene in 3T3-L1 adipocytes (34). In the present study we
demonstrate that in human adipose tissue, like in skeletal mus-
cle (30, 33), insulin infusion at supraphysiological concentra-
tion increases Glut 4 mRNA levels suggesting that insulin ex-
erts a positive control on Glut 4 gene expression in human
tissues. The insulin-induced increase in Glut 4 mRNA levels
reinforces the observation of an absence of effect on leptin
mRNA and strongly suggests that ob gene expression is not
acutely regulated by insulin in vivo in humans.
The lack of regulation of ob gene expression by caloric re-
striction and by insulin is in marked contrast to the observed
changes in leptin expression induced by similar protocols in ro-
dents (12–16). In these latter models, it is clear that leptin is a
satiety factor that controls food intake and energy expenditure
(6–10). It is suggested that these effects are mediated via inter-
action of leptin with its specific receptor in the hypothalamus
(11) resulting in changes in the levels of neuropeptide Y (35), a
major inducer of appetite. Our results suggest that care should
be taken to extrapolate this model, based on studies in rodents,
to the in vivo situation in man.
In summary, our data show that a precise quantification of
leptin mRNA level can be performed in small biopsies of adi-
pose tissue in human. Leptin mRNA levels are correlated with
Downloaded from http://www.jci.org on January 11, 2016.   http://dx.doi.org/10.1172/JCI118786
Regulation of ob Gene Expression in Human Adipose Tissue 255
the body mass index and are eight times higher in obese than
in lean subjects. However, ob gene expression is not affected
by insulin infusion nor by 5 d of caloric restriction, suggesting
that leptin is not a tightly controlled satiety factor but rather a
consequence or a concomitant of the size of the fat deposit in
human.
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